- Home
- EWTX vs OMCL Comparison
EWTX vs OMCL Comparison
Compare EWTX & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- OMCL
- Stock Information
- Founded
- EWTX 2017
- OMCL 1992
- Country
- EWTX United States
- OMCL United States
- Employees
- EWTX N/A
- OMCL N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- EWTX Health Care
- OMCL Technology
- Exchange
- EWTX Nasdaq
- OMCL Nasdaq
- Market Cap
- EWTX 1.2B
- OMCL 1.3B
- IPO Year
- EWTX 2021
- OMCL 2001
- Fundamental
- Price
- EWTX $14.28
- OMCL $30.37
- Analyst Decision
- EWTX Buy
- OMCL Buy
- Analyst Count
- EWTX 8
- OMCL 6
- Target Price
- EWTX $40.13
- OMCL $44.83
- AVG Volume (30 Days)
- EWTX 1.1M
- OMCL 881.0K
- Earning Date
- EWTX 05-08-2025
- OMCL 05-06-2025
- Dividend Yield
- EWTX N/A
- OMCL N/A
- EPS Growth
- EWTX N/A
- OMCL N/A
- EPS
- EWTX N/A
- OMCL 0.45
- Revenue
- EWTX N/A
- OMCL $1,135,755,000.00
- Revenue This Year
- EWTX N/A
- OMCL $3.84
- Revenue Next Year
- EWTX N/A
- OMCL $3.98
- P/E Ratio
- EWTX N/A
- OMCL $67.05
- Revenue Growth
- EWTX N/A
- OMCL 3.00
- 52 Week Low
- EWTX $10.60
- OMCL $22.66
- 52 Week High
- EWTX $38.12
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- EWTX 43.22
- OMCL 55.02
- Support Level
- EWTX $13.80
- OMCL $29.18
- Resistance Level
- EWTX $14.68
- OMCL $29.92
- Average True Range (ATR)
- EWTX 0.78
- OMCL 1.18
- MACD
- EWTX 0.08
- OMCL 0.48
- Stochastic Oscillator
- EWTX 29.68
- OMCL 89.62
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.